Outcome of Allogeneic Hematopoietic Stem Cell Transplantation
Launched by THE UNIVERSITY OF HONG KONG · Nov 20, 2024
Trial Information
Current as of September 03, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the outcomes of a treatment called allogeneic hematopoietic stem cell transplantation (allo-HSCT), which is a procedure where a patient receives stem cells from a donor to help treat various blood disorders. The trial will collect important information about patients who have undergone this type of transplant at Queen Mary Hospital, including how well the treatment works and any related therapies.
To participate in this study, you need to be an adult (18 years or older) who has received an allo-HSCT. Unfortunately, if you are unable to provide informed consent, you won’t be eligible to join. If you take part, you can expect to share your medical history and experiences related to your treatment, which will help researchers understand the effectiveness of this procedure better. The study is currently recruiting participants, and all genders are welcome to apply.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients aged 18 years or older who received allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Exclusion Criteria:
- • participant who is unable to give informed consent in a prospective cohort.
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Harry HS Gill, MBBS, MD, FRCP, FRCPath
Principal Investigator
Department of Medicine, the University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported